Novartis Ag

Edward Karol Dziadulewicz

Christopher Thomas Brain

Andrew James Culshaw

Terance William Hart

Timothy John Ritchie

Liladhar Murlidhar Waykole

Lee Edwards

William Cantrell

Ulrich Schopfer

Christopher T Brain

The present specification relates to the use of a quinazolinone compound of the formula (I) wherein R, R, R, R, Rand m are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in acid addition salt form. 

Substituted quinazolinones as vanilloid antagonists

The present invention relates to the use of a quinazolinone compound of the formula (I) wherein R, R, R, R, Rand m are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in acid addition salt form, as a vanilloid. 

Quinazolinone derivatives useful as vanilloid antagonists

Novel quinazolinone derivatives of formula I wherein R-Rare as defined in the description, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them.

Quinazolinone derivatives and their use as CB agonists

The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their use as medicaments and to medicaments comprising them.

Chromone derivatives useful as antagonists of VR1 receptors

The present invention relates to novel naphthalene derivatives of formula (I), wherein R, R, Rand X are as defined in the description, and preparation thereof. The compounds of formula (I) are useful as pharmaceuticals.

Naphthalene derivatives

The invention relates to sulfonyl amine derivatives of formula IAwherein R, X, X, Rand Rare as defined herein, which derivatives are useful as bradykinin Breceptor antagonists.

Growing community of inventors

Horsham, United Kingdom

Edward Karol Dziadulewicz